trending Market Intelligence /marketintelligence/en/news-insights/trending/MAr22mitf_Mgtr5jKjq8SA2 content esgSubNav
In This List

ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

ContraVir Pharmaceuticals Inc. said it was evaluating its options after its stocks fell out of compliance with Nasdaq's minimum bid listing requirement of $1 per share.

The company has until Dec. 4 to regain compliance and may be eligible for a further extension.

The notice has no immediate effect on the company's listing on the stock market.